Frataxin gene (FXN) (FXN)

The Frataxin (FXN) gene locus, located on chromosome 9q21.11, is the genetic site responsible for encoding the frataxin protein, which is essential for mitochondrial iron-sulfur cluster assembly [1, 2]. In Friedreich's ataxia (FRDA), the locus typically contains an expanded GAA triplet repeat in the first intron, leading to epigenetic silencing and a significant reduction in frataxin expression [3, 4]. This deficiency results in mitochondrial dysfunction, impaired energy production, and increased oxidative stress, primarily affecting the dorsal root ganglia, cerebellum, and heart [1, 3]. Therapeutic interventions targeting this locus aim to restore frataxin levels through gene therapy, which delivers a functional copy of the gene, or through epigenetic modifiers like HDAC inhibitors that reactivate the silenced endogenous gene [4, 6]. Additionally, small molecules like omaveloxolone target downstream pathways or transcription factors to improve mitochondrial function and indirectly boost FXN expression [5]. Successful modulation of the FXN gene locus is critical for treating the underlying cause of FRDA and preventing progressive neurological and cardiac deterioration [3, 6]. Sources: [1] UniProt (Q16595); [2] NCBI Gene (ID: 2395); [3] NIH/GARD (Friedreich Ataxia); [4] PubMed (PMID: 30635110); [5] FDA (Skyclarys/Omaveloxolone); [6] ClinicalTrials.gov (LX2006).

Other names

FXNFRDAX25CyaYFriedreich ataxia geneFA

Transcriptional reactivation via epigenetic modification, gene replacement therapy using viral vectors, or Nrf2-mediated induction of gene expression to restore frataxin protein levels.